Great to see some movement here in the news department for LCT.
If my investment in another ASX biotech has taught me anything, it's the people that companies appoint that will be the foundation for the future.
In my first glance into researching Dr Mckenna, I found some info mentioning him in an ASX Hexima (HXL) Filing from 2017
"During the year Hexima announced the commencement of a project to assess the application of Hexima’s antifungal technology for control of medically important Candidaemias and Candida-based biofilms. Systemic Candida infections are a major problem in immunocompromised patients where they are associated with high morbidity and mortality. These infections often arise from biofilms that form on cannulas, catheters and surgical implants and which are difficult to treat with standard antifungal therapies. Early work on this project has identified several plant defensins that kill Candida biofilms.
Hexima will continue to assess the activity and safety profile of these defensins with the aim of progressing promising candidates into pre-clinical
proof-of-concept animal models. The Candida project is partially funded by a Science and Industry Endowment Fund STEM+ Business Fellowship awarded to
Dr James McKenna Q4, 2016. This fellowship will allow
Dr McKenna, an early career researcher based at the
La Trobe Institute for Molecular Science (LIMS), to work with Hexima to investigate novel applications of the plant defensin technology. Hexima also expects
to receive proof-of-concept results from animal studies for the application of plant defensins for treatment of vaginal thrush in Q3, 2017.
https://www.annualreports.com/HostedData/AnnualReportArchive/h/ASX_HXL_2017.pdf
The ASX company (Hexima) also had me thinking I knew that name from another source haha!
DR Mark Bleackley who is currently Chief Scientific Officer at Incannex also spent some years at Hexima.
I noticed some possible overlaps in the career paths of both gentlemen.
https://au.linkedin.com/in/mark-bleackley-b84963114?original_referer=https://www.google.com/
Now all investors need to do their own research.
But from my initial work, I think Dr James McKenna and Dr Mark Bleackley's connection/overlapping career paths is a good one.
Because IMO Dr Mark has been an MVP in the Incannex Research Team.
If Dr James can bring his experience to LCT as Dr Mark has to IHL, then it is definitely a step in the right direction.
Good luck to all holders and good luck to Dr James!
(20min delay)